About Arcutis
Strategic
Collaborators
AstraZeneca
Arcutis and AstraZeneca have entered into a licensing agreement for exclusive worldwide rights to all topical dermatological uses of roflumilast, including the exclusive right to commercialize any resulting products.
Jiangsu Hengrui Medicine Co., Ltd.
In December 2019, Arcutis exercised its option under a 2018 License Agreement with Jiangsu Hengrui Medicine Co., Ltd. of China (Hengrui) for an exclusive license to the active pharmaceutical ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), for all topical dermatological uses in the United States, Canada, Europe, and Japan. Under the license, Arcutis has the exclusive right to commercialize any resulting products in these territories. Arcutis plans to develop ARQ-252 for hand eczema and other inflammatory dermatoses.
Meaningful innovation at a glance.
Download our corporate fact sheet.
Download